Journal article

Area-level socioeconomic status and incidence of abnormal glucose metabolism: The Australian Diabetes, Obesityand Lifestyle (AusDiab) study

ED Williams, DJ Magliano, PZ Zimmet, AM Kavanagh, CE Stevenson, BF Oldenburg, JE Shaw

Diabetes Care | American Diabetes Association | Published : 2012


OBJECTIVE: To examine the role of area-level socioeconomic status (SES) on the development of abnormal glucose metabolism (AGM) using national, population-based data. RESEARCH DESIGN AND METHODS: The Australian Diabetes, Obesity and Lifestyle (AusDiab) study is a national, population-based, longitudinal study of adults aged ≥25 years. A sample of 4,572 people provided complete baseline (1999 to 2000) and 5-year follow-up (2004 to 2005) data relevant for these analyses. Incident AGM was assessed using fasting plasma glucose and 2-h plasma glucose from oral glucose tolerance tests, and demographic, socioeconomic, and behavioral data were collected by interview and questionnaire. Area SES was ..

View full abstract


Awarded by Diabetes UK Fellowship

Awarded by National Health and Medical Research Council (NHMRC) Health Services Research Grant

Awarded by NHMRC Fellowship

Awarded by NHMRC

Awarded by Diabetes UK

Funding Acknowledgements

E.D.W. is supported by a Diabetes UK Fellowship (09/0003833). D.J.M. is supported by the Victorian Cancer Agency Fellowship for 2011. C.E.S. is supported by National Health and Medical Research Council (NHMRC) Health Services Research Grant 456130. J.E.S. is supported by NHMRC Fellowship 586623. The AusDiab study, co-coordinated by the Baker IDI Heart and Diabetes Institute, gratefully acknowledges the generous support given by NHMRC Grant 233200, Australian Government Department of Health and Ageing, Abbott Australasia Pty Ltd, Alphapharm Pty Ltd, AstraZeneca, Bristol-Myers Squibb, City Health Centre-Diabetes Service-Canberra, Department of Health and Community Services Northern Territory, Department of Health and Human Services Tasmania, Department of Health New South Wales, Department of Health Western Australia, Department of Health South Australia, Department of Human Services Victoria, Diabetes Australia, Diabetes Australia Northern Territory, Eli Lilly Australia, Estate of the Late Edward Wilson, GlaxoSmithKline, Jack Brockhoff Foundation, Janssen-Cilag, Kidney Health Australia, Marian and E.H. Flack Trust, Menzies Research Institute, Merck Sharp & Dohme, Novartis Pharmaceuticals, Novo Nordisk, Pfizer Pty Ltd, Pratt Foundation, Queensland Health, Roche Diagnostics Australia, Royal Prince Alfred Hospital, Sydney, sanofi-aventis, and Sanofi Synthelabo. The AusDiab study was also supported in part by the Victorian Government's Operational Infrastructure Support Program. No other potential conflicts of interest relevant to this article were reported.